4502
Fiscal year ends March Quarters are offset from the calendar — Q1 is Apr–Jun

Takeda Pharmaceutical Company Limited is a global research and development-focused biopharmaceutical company. It operates in a single pharmaceutical segment, conducting research, development, manufacturing, and sales of a broad portfolio of medicines. The company focuses on key therapeutic areas including gastroenterology, inflammatory diseases, neuroscience, and oncology, while also providing plasma-derived products and vaccines. Takeda addresses both rare and high-prevalence diseases through its pipeline. Key subsidiaries include Takeda Pharmaceuticals U.S.A., Inc., Vaxalta US Inc., Takeda Development Center Americas Inc., Takeda Pharmaceuticals International AG, and Takeda GmbH. The company serves markets in Japan, the United States, Europe, Canada, and China, utilizing local subsidiaries for regional operations.

Summarised from the annual report, fiscal year ended Mar 2026

Industry Drug Manufacturers - General Homepage takeda.com
Sector Healthcare IR page takeda.com
Tags
gastroenterology, inflammatory diseases, neuroscience, oncology, plasma-derived products, vaccines, rare diseases, biopharmaceuticals, Takeda Pharmaceuticals U.S.A. Inc., Vaxalta US Inc., Takeda Development Center Americas Inc., Takeda Pharmaceuticals International AG, Takeda GmbH, Takeda (China) International Trading Co. Ltd.
Press page takeda.com/jp/newsroom

Metrics

Valuation  
Market cap ¥ 9.195T
Market cap (USD) $ 57.724B
P/E 237.05
PEG —
P/BV 1.24
P/S 1.96
P/OCF 10.45
P/FCF 21.01
Dividend yield 3.5%
Turnover / mcap —
Returns  
ROE -2.1%
ROI -1.2%
ROIC 0.04%
Profit margin -3.4%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 70
Quality score -47.4%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 4.506T 4.582T 4.264T 4.027T 3.569T 3.198T 3.291T 2.097T 1.771T 1.732T 1.807T 1.778T 1.692T 1.557T
Net profit -152.39B 107.928B 144.067B 317.017B 230.059B 376.005B 44.241B 109.126B 186.886B 114.94B 80.166B -145.775B 90.348B 131.244B
Free cash flow 630.498B 709.341B 235.614B 343.467B 937.068B 774.463B 452.042B 194.365B — — — — — —

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 5.663K 4.415K 4.181K 4.349K 3.504K 3.987K 3.306K 4.521K 5.183K 5.227K 5.133K 5.998K 4.892K 5.036K
Price performance 12m 0.28 0.06 -0.04 0.24 -0.12 0.21 -0.27 -0.13 -0.01 0.02 -0.14 0.23 -0.03 —

Filed figures

Figure Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Balance sheet detail
Borrowings, current (JPY) — 18M 985B 587B 22.2B 204B 340B 367B 549B 512B
Borrowings, non-current (JPY) — 986B 4.77T 4.51T 4.61T 4.14T 4.04T 4.48T 3.97T 4.37T
Cash and deposits (JPY) 319B 295B 702B 638B 966B 850B 534B 458B 385B 595B
Intangible assets (JPY) — 1.01T 4.86T 4.17T 3.91T 3.82T 4.27T 4.27T 3.63T 3.42T
Net debt (borrowings + leases - cash) (JPY) — 691B 5.05T 4.46T 3.67T 3.5T 3.85T 4.39T 4.13T 4.29T
Cash flow detail
Operating cash flow (JPY) 261B 378B 328B 670B 1.01T 1.12T 977B 716B 1.06T 1.04T
Purchases of property, plant and equipment (JPY) — -67B -77.7B -127B -111B -123B -141B -175B -201B -176B
Purchases of intangible assets (JPY) — -61.3B -56.4B -90.6B -125B -62.8B -493B -305B -147B -235B
Change in inventories (cash effect) (JPY) — 13.7B 58.7B 137B 26B -46.1B -79.2B -116B -35B -61.3B
Dividends paid (cash effect) (JPY) — -142B -143B -283B -283B -284B -279B -287B -302B -312B
Share buybacks (cash effect) (JPY) — -18.8B -1.17B -3.74B -2.14B -77.5B -26.9B -2.33B -51.9B -51.6B
Income taxes paid (cash effect) (JPY) — -54.9B -51.5B -235B -236B -148B -198B -220B -171B -180B
Share-based compensation (JPY) — — 20.1B 29.1B 37.7B 43.4B 60.7B 70.9B 72.9B 72.8B
Free cash flow (OCF - PPE - intangibles) (JPY) — 250B 194B 452B 774B 937B 343B 236B 709B 630B
Income detail
Research and development expense (JPY) — 325B 368B 492B 456B 526B 633B 730B 730B 676B
↳ 5y CAGR +14.2% +14.7% +8.2% +8.2%
Total comprehensive income (JPY) 93.1B 243B 99.2B -199B 697B 824B 912B 1.14T -57.7B 780B
Comprehensive income to owners (JPY) — 242B 99.5B -200B 697B 824B 912B 1.14T -57.9B 780B
Reported Jun 29, 2017 Jun 27, 2019 Jun 24, 2020 Jun 24, 2020 Jun 29, 2021 Jun 29, 2022 Jun 28, 2023 Jun 26, 2024 Jun 25, 2025 Jun 17, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Definition of Non-IFRS Measures Bull 0 Bear 0 Routine

Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations A-1

Reconciliations and Other Financial Information

FY2026 H1 Reported Results with CER % Change A-4

FY2026 Q2 (Jul - Sep) Reported Results with CER % Change A-5

FY2026 H1 Core Results with CER % Change A-6

FY2026 Q2 (Jul-Sep) Core Results with CER % Change A-7

FY2026 H1 Reconciliation from Reported to Core A-8

FY2026 Q2 (Jul-Sep) Reconciliation from Reported to Core A-9

FY2025 H1 Reconciliation from Reported to Core A-10

FY2025 Q2 (Jul-Sep) Reconciliation from Reported to Core A-11

FY2026 H1 Adjusted Free Cash Flow A-12

FY2026 H1 Adjusted Net Debt to Adjusted EBITDA

A-13

FY2025 Adjusted Net Debt to Adjusted EBITDA

A-14

FY2026 H1 Net Profit to Adjusted EBITDA Bridge A-15

FY2026 H1 Net Profit to Adjusted EBITDA LTM Bridge A-16

FY2026 H1 CAPEX, Depreciation and Amortization and Impairment Losses A-17

FY2026 Full Year Detailed Forecast A-18

FY2026 Full Year Reconciliation from Reported Operating Profit to Core Operating Profit Forecast A-19

FY2026 Full Year FX Rates Assumptions and Currency Sensitivity vs.

Prompts

Takeda Pharmaceutical Company Limited (ticker 4502), listed in Japan.

Company History

Date Change Detail
Nov 1, 2018 Acquired Acquired Shire PLC (EDINET code 936402). Its filings from before the deal are on its own company page, not shown here.
Feb 13, 2017 Acquired Acquired Ariad Pharmaceuticals Inc (EDINET code 884731). Its filings from before the deal are on its own company page, not shown here.

ETFs Holding Takeda Pharmaceutical Company Limited

ETF Weight in ETF Shares Market value As of
BINV 2.35% 363,000 $ 11.509M Jun 30, 2026
DTAN 1.78% 8,886 $ 386.513K Nov 17, 2026
GDMA 1.08% 92,962 $ 2.01M Nov 18, 2026
GINX 0.72% 42,787 $ 769.31K Aug 31, 2026
DFIV 0.68% 3,590,849 $ 153.268M Nov 12, 2026
GPT 0.64% 9,439 $ 151.307K Jun 30, 2026
AIVI 0.63% 11,600 $ 367.931K Jun 30, 2026
RCGE 0.55% 12,566 $ 550K Nov 18, 2026
RFDI 0.53% 25,500 $ 883.577K Jul 31, 2026
CGIC 0.52% 302,200 $ 13.145M Nov 16, 2026
JSTC 0.44% 59,597 $ 1.287M Nov 17, 2026
NTSI 0.26% 41,000 $ 1.3M Jun 30, 2026
APIE 0.26% 168,346 $ 3.027M Aug 31, 2026
DFAI 0.23% 997,300 $ 42.568M Nov 12, 2026
IVSI 0.22% 552 $ 17.501K Jun 30, 2026
GEW 0.22% 8,965 $ 323.526K Aug 31, 2026
DFSI 0.20% 56,000 $ 2.39M Nov 12, 2026
DFIC 0.14% 510,200 $ 21.626M Nov 12, 2026
DFAX 0.09% 270,072 $ 11.414M Nov 12, 2026
DXIV 0.07% 4,200 $ 179.268K Nov 12, 2026
AVSD 0.07% 12,195 $ 263.29K Nov 16, 2026
AVDE 0.06% 570,350 $ 12.314M Nov 16, 2026
BDYN 0.06% 89,853 $ 1.94M Nov 16, 2026

Securities

Ticker Type Class Market Exchange Last price Price date
TAK Common share — US nyse 18.19 USD 2026-09-30
4502 canonical Common share — JP tsej 5,739.00 JPY 2026-09-29
TKPHF Common share — US otc — —